Introduction
============

Mitochondria play a key role in the pathogenesis of many diseases ([@B163]; [@B93]; [@B94]; [@B127]; [@B14]) and aging ([@B75]). The number of mitochondria and the amount of mtDNA rapidly increase in the fetus, starting from the blastocyst stage ([@B119]) and continuing to grow over the entire period of organism development and maturation ([@B66]). However, there is still no consensus on what happens to the number of mitochondria with aging, since the data obtained in different tissues, at different stages, and with different methods are extremely controversial.

A number of authors report an age-related increase of the amount of mtDNA in skeletal muscle ([@B11]; [@B115]). Studies based on electron microscopy have not shown any age-related changes in the number of mitochondria in skeletal muscle ([@B98]; [@B20]). However, [@B33] showed a decrease of the number of mitochondrial copies in skeletal muscles of aged mice. Studies by [@B81] and [@B26] showed a decrease of the marker mitochondrial enzymes activity in skeletal muscle, and the authors concluded that the number of mitochondria decreases in aging. Opposite conclusions made by various research groups may be associated not only with different methods for determining the number of mitochondria, but also with structural, biochemical and functional heterogeneity of skeletal muscles ([@B67]). Studies using electron microscopy showed a decrease of the number of mitochondria in the heart ([@B153]; [@B33]), whereas others did not reveal any changes ([@B139]). However, there is no doubt that the area of the inner mitochondrial membrane decreases with age in heart ([@B136]; [@B131]). In the brain, age-related decrease of the number of mitochondria was found using electron microscopy ([@B18]), enzymatic methods ([@B55]; [@B88]; [@B37]) and estimation of expression of genes encoded by mtDNA ([@B113]; [@B62]).

We should emphasize that it is not only the number of mitochondria that is important, but also their functional state, which depends on mitochondrial biogenesis and dynamics, including fission/fusion and mitophagy. The dysregulation of these processes leads to age-related decrease in mitochondrial volume density and oxidative capacity per mitochondrial volume ([@B32]). The coordination between these processes is controlled by several mutually regulated signaling cascades, one of the most important being the Nrf2/ARE cascade ([@B70]). Despite a growing interest in this signaling pathway, there are only a few reviews on the key role of Nrf2 in mitochondrial biogenesis and its interactions with the more studied "master regulator of mitochondrial biogenesis" PGC-1α ([@B135]).

Regulation of Mitochondrial Biogenesis by the PGC-1α-Signaling Cascade
======================================================================

Mammalian mtDNA is a circular DNA molecule of approximately 16.5 kb that possesses its own translational/transcriptional system, including 2 rRNA genes and 22 tRNA genes. It also has the non-coding region, the so-called D-loop, that contains the mtDNA replication origin and the transcription initiation site ([@B31]).

Replication is performed by the mtDNA polymerase γ (POLG) consisting of the catalytic subunit encoded by the *POLG* gene and auxiliary dimeric subunit encoded by the *POLG2* gene ([@B60]). mtDNA is transcribed by the mitochondrial RNA polymerase POLRMT ([@B158]). The key enhancer protein is TFAM (transcription factor A, mitochondrial), which ensures mtRNA unwinding and flexing required for the POLRMT binding to the mtDNA promoters. TFB2M (transcription factor B2, mitochondrial) acts as a specific dissociation factor that provides interaction between POLRMT and TFAM. Both TFB1M and TFB2M bind rRNA dimethyltransferases and, therefore, can function as rRNA modifiers ([@B128]). It was suggested that the major role of TFB1M is rRNA methylation and not its transcription factor function ([@B102]).

Nuclear respiratory factors NRF1 and NRF2 regulate expression of the electron transfer chain (ETC) subunits encoded by the nuclear genome ([@B47]) and bind to the promoters of genes involved in mtDNA transcription. NRF1 binds to the specific promoter sites and regulates expression of TFAM ([@B161]), TFB1M, and TFB2M ([@B58]). Besides, nuclear respiratory factors, in particular NRF2, regulate expression of other mitochondrial enzymes, e.g., TOMM20 (translocase outer mitochondrial membrane), a key enzyme in the mitochondrial membrane transport ([@B13]). In turn, NRF1 and NRF2 are regulated by transcription coactivators, the most studied of which is PGC-1α ([@B137]).

PGC-1α was discovered as a coregulator of PPARγ expressed in the brown fat at low temperatures that mediates adaptive thermogenesis (hence the name PGC-1α---**P**PAR-**G**amma-**C**oactivator-**1α)**. Later, it was found that PGC-1α acts as a coactivator for a much larger number of genes. It was demonstrated that PGC-1α interacts with both NRF1 and NRF2. Deletion of the *N*-terminal fragment in NRF1 abolishes the PGC-1α effect on mitochondrial biogenesis ([@B175]).

PGC-1α is regulated on both the transcription and post-translation levels ([@B50]). Cold exposure activates the sympathetic nervous system through β3-adrenergic receptor (β3-AR), which contributes the activation of protein kinase A (PKA). PKA activates CREB, which regulates the expression of PGC-1α directly ([@B124]; [@B16]; [@B68]). p38 MAPK is another factor that regulates the expression of PGC-1α. It activates myocyte enhancer factor 2 (MEF2), which has the site of binding with the promoter of PGC-1α ([@B63]). MEF2 can activate p38 mitogen-activated protein kinase (p38 MAPK) in skeletal muscle ([@B182]). Additionally, p38 MAPK can regulate the expression of PGC-1α by activating transcription factor 2 (ATF2) ([@B3]). An increase in the intracellular Ñà^2+^ concentration in skeletal muscle activates Ñà^2+^/calmodulin-dependent protein kinase (CaMK), which activates the expression of PGC-1α via CREB ([@B114]) ([Figure 1](#F1){ref-type="fig"}).
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AMP-activated protein kinase (AMPK) is the major factor of PGC-1α post-translation modification for a wide range of tissue. PGC-1α phosphorylation is only one of the mechanisms of mitochondrial biogenesis activation via AMPK ([@B73]). AMPK can increase the level of NAD^+^, which results in SIRT1 phosphorylation. Activated SIRT1 deacetylates PGC-1α, thereby promoting mitochondrial biogenesis ([@B22]). p38 MAPK cannot only regulate the expression of PGC-1α, but also phosphorylates and so activates PGC-1α ([@B123]). Another activator of PGC-1α is cGMP, which is upregulated due to the increase in the concentration of nitric oxide (NO) produced by NO synthases iNOS and eNOS ([@B111]) ([Figure 1](#F1){ref-type="fig"}).

Phosphorylation of PGC-1α can also lead to its negative regulation. PGC-1α is phosphorylated by glycogen synthase kinase 3β (GSK3β), which inhibits PGC-1α and contributes to its intranuclear proteasomal degradation ([@B4]). However, negative regulation of PGC-1α is carried out because of acetylation to a greater extent. GCN5 (general control of amino acid synthesis 5) is one of the most important molecules that carry out the acetylation of PGC-1α, which subsequently deacetylates by SIRT1 ([@B132]).

PGC-1β does not have such a wide range of action as PGC-1α, in particular it is not activated in brown fat upon cold exposure ([@B99]). However, PGC-1β regulates the expression of NRF1 and mitochondrial biogenesis ([@B92]). The level of mitochondrial biogenesis is extremely high in transgenic mice, overexpressing PGC-1β, which even leads to the disorganization of the myofibrillar apparatus ([@B6]).

Major Properties of the Nrf2/ARE Signaling Cascade
==================================================

ARE (antioxidant response element) is a promoter element in various genes. The major activator of ARE was named Nrf2 (NF-E2-p45-related factor 2, encoded by *NFE2L2* gene) ([@B57]). Nrf2 localizes to the cytoplasm, where it binds the specific inhibitor Keap1. In the absence of activation, Nrf2 is ubiquitinated by the E3-ubiquitin ligase-like domain of Keap1 and degraded by the 26S proteasome ([@B179]); therefore, Keap1 acts as a negative regulator of Nrf2. Nrf2 activation requited oxidation of SH-groups in Keap1 ([@B80]). Free Nrf2 is translocated to the nucleus, where it forms a heterodimer with the small protein Maf and binds to AREs in the target gene promoters. In most cases, these are genes coding for proteins with cytoprotective properties, e.g., antioxidant enzymes, proteins of phase II xenobiotic detoxication, and antiinflammatory enzymes. Nrf2 also regulates expression of genes involved in the regulation of redox homeostasis and a number of metabolic enzymes ([@B40]).

Another well-described Nrf2 repressor is GSK3β. Unlike most protein kinases, GSK3β is active under non-stress conditions and can phosphorylate Nrf2, thereby suppressing its translocation to the nucleus. However, GSK3β-induced suppression of Nrf2 can be abolished by Akt/PKB that inhibits GSK3β ([@B154]). The E3 ubiquitin ligase Hrd1 is the third negative regulator of Nrf2, which contributes to its ubiquitination and degradation ([@B174]).

Nrf2-Dependent Mitochondrial Biogenesis
=======================================

The idea that the Nrf2/ARE signaling cascade is involved in mitochondrial biogenesis is relatively new. Only in [@B118] for the first time suggested the role of Nrf2 in the activation of mitochondrial biogenesis. The powerful incentive for the development of this field of research was the discovery of four AREs in the *NRF1* gene promoter that were capable of Nrf2 binding. The CO-stimulated production of H~2~O~2~ results in PTEN oxidation, leading to Akt/PKB activation. Akt phosphorylates and inactivates GSK3β, thereby promoting Nrf2 translocation to the nucleus. In the nucleus, Nrf2 binds to the *NRF1* promoter AREs. NRF1 activates TFAM, which is directly involved in the mtDNA replication ([Figure 1](#F1){ref-type="fig"}).

Later, Akt phosphorylation with the following activation of the Nrf2-dependent mitochondrial biogenesis was demonstrated in heart failure treatment ([@B21]). CO has a therapeutic effect on *Staphylococcus aureus*-caused sepsis because of the increase of expression levels of *HO-1*, both nuclear respiratory factors (*NRF1* and *NRF2*) and *TFAM*. This effect was detected neither in Nrf2-deficient nor in Akt-deficient mice ([@B96]).

###### 

Activation of mitochondrial biogenesis via Nrf2/ARE signal pathway.

  Activation of Nrf2                   Organ or cell line             Physiological condition                 References
  ------------------------------------ ------------------------------ --------------------------------------- ------------
  CO-stimulated H~2~O~2~ production    Heart                          Non-diseased                            [@B118]
  H~2~S                                Heart                          Heart failure                           [@B21]
  CO                                   Liver                          *Staphylococcus aureus-*caused sepsis   [@B96]
  Acetyl-[L]{.smallcaps}-carnitine     Brain                          Hypoxia                                 [@B71]
  Dimethyl fumarate                    Brain                          MPTP-induced Parkinson's disease        [@B2]
  Quercetin                            Brain                          Traumatic brain injury                  [@B89]
  Methylene blue                       Brain                          Non-diseased mid-aged mice              [@B62]
  Physical exercise                    Brain                          6-OHDA-induced Hemiparkinsonism         [@B1]
  Grape powder                         Kidney                         Non-diseased mid-aged rats              [@B120]
  Physical exercise                    Skeletal muscle                Non-diseased                            [@B100]
  PNU282987                            Glial cells                    Non-diseased                            [@B107]
  Sulforaphane                         Cells LLCPK1 and PC3           Prostate cancer                         [@B109]
  Physical exercise                    Skeletal muscle                Non-diseased                            [@B185]
  *Nox4* downregulation                Lung Fibroblasts               Non-diseased                            [@B12]
  Dimethyl fumarate                    Peripheral blood lymphocytes   Multiple sclerosis                      [@B65]
  Acute effect of severe burn trauma   Liver                          Burn trauma                             [@B15]
  β-Guanidinopropionic acid            Brain                          Mid-aged mice                           [@B61]

Different Nrf2 activators were found to regulate mitochondrial biogenesis in different organs. Dimethyl fumarate disrupts the interaction between Keap1 and Nfr2 by alkylating cysteine residues in Keap1, which results in Nrf2 translocation to the nucleus and activation of mitochondrial biogenesis in multiple sclerosis ([@B65]) and MPTP-induced model of Parkinson's disease ([@B2]). Quercetin and acetyl-[L]{.smallcaps}-carnitine induce Nrf2-dependent mitochondrial biogenesis in traumatic brain injury ([@B89]) and hypoxia ([@B71]), respectively. Methylene blue ([@B62]) and β-guanidinopropionic acid ([@B61]) promote mitochondrial biogenesis in the brain of middle-aged (15-month-old) mice by inducing mild oxidative and energy stress in the mitochondria. Sulforaphane increases the number of mitochondria in cancer cells ([@B109]). The α7-nicotinic acetylcholine receptor agonist PNU282987 activates mitochondrial biogenesis in cultured glial cells ([@B107]). Moderate physical exercise induces Nrf2-dependent mitochondrial biogenesis in muscles ([@B100]; [@B185]) and in the striatum in the 6-OHDA-induced model of parkinsonism ([@B1]). Nrf2-dependent mitochondrial biogenesis is activated during tissue regeneration after burn trauma ([@B15]). Downregulation of the *Nox4* gene expression also promotes Nrf2-dependent mitochondrial biogenesis ([@B12]) ([Table 1](#T1){ref-type="table"}).

The key role of Nrf2 in mitochondrial biogenesis has also been demonstrated using Nrf2-deficient animal models. In contrast to the wild-type animals, Nrf2 activators did not increase the amounts of mitochondrial markers in the Nrf2−/− mutants ([@B8]; [@B96]; [@B27]; [@B2]; [@B107]). It was found that Nrf2 deficiency impairs mitochondrial biogenesis in the intestine of Nrf2−/− mice ([@B27]).

A decrease in the intensity of mitochondrial biogenesis due to impaired Nrf2 translocation to the nucleus was observed in the gentamycin-induced nephrotoxicity ([@B108]), hypertonia caused by injection of low doses of lipopolysaccharide ([@B173]), multiple sclerosis ([@B65]), and in placentas of women suffering from diabetes combined with obesity ([@B42]).

Interaction Between the Nrf2 and PGC-1α Signaling Pathways
==========================================================

It was found that Nrf2 translocation to the nucleus is strictly regulated by the activity of AMPK. AMPK phosphorylates Nrf2 at Ser50, which results in GSK3β inactivation. Both processes are essential for Nrf2 translocation to the nucleus ([@B78]). It was demonstrated that berberine ([@B103]), aldose reductase inhibitor fidarestat ([@B143]), and pterostilbene (antioxidant from blueberries) ([@B84]) activate Nrf2, and this activation is controlled by AMPK. AMPK inhibition abolishes Nrf2 activation ([@B165]).

It is most probable that Nrf2 is indeed controlled by PGC-1α. [@B5] showed that PGC-1α controls the antioxidant genes through Nrf2 activation; thus, downregulation of PGC-1α expression almost completely inhibits Nrf2 binding to the GCLC gene ARE and decreased the content of SOD2 and GCL proteins. Mice heterozygous by PGC-1α (*PGC-1*α^+/−^) exhibit downregulated expression of SOD2 because of the disrupted Nrf2 interaction with the *SOD2* gene ARE ([@B28]). It was found that PGC-1α knockout dysregulates the Nrf2-dependent mitochondrial biogenesis ([@B107]), although the mechanism of direct interaction between PGC-1α and Nrf2 remained unclear until recently. [@B30] demonstrated that PGC-1α activates Nrf2 via inhibition of GSK3β. GSK3β is inactivated by p38, which is positively regulated by PGC-1α. Therefore, the PGC-1α/p38/GSK3β/Nrf2 cascade is the most probable pathway connecting these two coregulators of mtDNA transcription.

It is also possible that Nrf2 and PGC-1α form the feedback loop, i.e., Nrf2 directly influences PGC-1α expression. The PGC-1α gene promoter contains two AREs: −1723 (5′-TCTTGA**TGACATTGC**TTCTG-3′) and −226 (5′-CTGATT**TGATGGAGC**TACTT-3′) ([@B10]). There are data that confirm the existence of the Nrf2/PGC-1α feedback loop. Thus, the siRNA-mediated suppression of Nrf2, as well as *Nrf2* knockout, inhibit mitochondrial biogenesis and downregulate PGC-1α expression in hepatocytes ([@B77]), skeletal muscles ([@B170]), and lungs infected with *S. aureus* ([@B8]).

There is evidence that both signaling cascades could be activated simultaneously. Metformin activates Nrf2 without involvement of the AMPK/PGC-1α axis, since inhibition of AMPK phosphorylation does not prevent metformin-induced Nrf2 activation ([@B122]). It is, however, commonly believed that the major effect of metformin is AMPK activation due to the changes in the AMP/ATP ratio ([@B117]).

Nrf2 and PGC-1α can be simultaneously activated via the Erk1/2 signaling cascade. Erk1/2 activates both Nrf2 and PGC-1α via phosphorylation of LKB1, which in turn phosphorylates AMPK ([@B71]). Interestingly, some commonly used pharmaceutical agents, e.g., erythropoietin (EPO), regulate the antioxidant defense via the Erk1/2/Nrf2/ARE axis ([@B54]; [@B76]; [@B171]). On the other hand, it was found that EPO activates mitochondria biogenesis through the Akt/eNOS/PGC-1α ([@B23]; [@B126]) and AMPK/PGC-1α ([@B164]) pathways. Therefore, EPO can potentially activate both the Nrf2 and PGC-1α cascades. Moreover, both cascades have a common point: Akt phosphorylation can activate Nrf2 via GSK3β phosphorylation ([@B118]) and directly activate eNOS ([@B155]). Methylene blue is another compound which contributes to activation of mitochondrial biogenesis through Nrf2 by stimulation of H~2~O~2~ production ([@B62]) and changing the relation NAD^+^/NADH, which leads to PGC-1α activation through phosphorylation by AMPK ([@B7]).

An important study on the relation between PGC-1α and Nrf2 in mitochondrial biogenesis was published by [@B100]. It is known that physical exercise induces formation of reactive oxygen species (ROS) (mostly, H~2~O~2~) and nitric oxide (NO). The authors demonstrated that treatment of Nrf2^−/−^ cells with the NO and H~2~O~2~ donors failed to cause mitochondrial biogenesis activation. siRNA-mediated suppression of PGC-1α prevented NO-induced, but not H~2~O~2~-induced, activation of mitochondrial biogenesis ([@B100]). Therefore, even in the case of the same event (physical exercise), mitochondrial biogenesis can be activated by different mechanisms involving different secondary messengers (Ca^2+^, NO, H~2~O~2~) ([Figure 1](#F1){ref-type="fig"}). Both Nrf2 and PGC-1α were found to be activated simultaneously during mitochondrial biogenesis induced by exercise ([@B185]) and burn trauma ([@B15]).

Simultaneous activation of Nrf2 and PGC-1α pathways may be one of the most promising directions in gerontoprotection. In general, it relates with the fact that these two transcription factors in sum are able to regulate almost all aspects related to the functioning of mitochondria.

Role of Nrf2 and PGC-1α in Aging
================================

The major postulates of the aging theory were published by Harman over 50 years ago. He stated that an increase in the intensity of free-radical processes with age results in the accumulation of oxidative damage and tissue degeneration, i.e., aging ([@B64]). Since then, the theory expanded because of new experimental data that do not refute, but modify and refine this theory. There is widespread agreement that one of symptoms of aging is the accumulation of damaged mitochondria ([@B95]; [@B145]). For this reason, the theory of a mitochondrial "vicious cycle" became a logical continuation of Harman's theory. Age-related increase of ROS production causes an increase of the frequency of mtDNA mutations, and they lead to ETC dysfunction, which leads to even more ROS production ([@B168]). Despite the logicality of this theory, it is not fully supported by experimental data ([@B145]). In particular, the initiation of mtDNA mutations does not cause an increase of the rate of ROS production, although it led to disruption of the functioning of the respiratory complexes, inhibition of membrane potential generation and ATP synthesis ([@B69]). Ubiquinone depletion leads to impaired mitochondrial function, but on the contrary leads to a decrease of the rate of H~2~O~2~ production ([@B166]). These studies suggest that among all age-related mitochondrial dysfunctions, an increase of ROS production is not the most influential.

An age-related decrease of the activity of the mitochondrial respiratory chain complexes was observed almost in all studies. It is noteworthy that there is a decrease in the activity of not all components, but mainly NADH dehydrogenase ([@B55]; [@B106]; [@B134]) and COX ([@B106]; [@B49]). The decrease of the COX activity is associated with a shift of the ETC redox balance toward over-reduction. It stimulates electron leakage from ETC and subsequent ROS hyperproduction. A decrease of the complex I activity, on the contrary, may lead to a decrease of ROS production, which also has negative consequences ([@B145]). ROS, in particular H~2~O~2~, are important signaling molecules involved in the inactivation of negative regulators of Nrf2. An age-related decline of ROS production can lead to dysregulation of the feedback system of adaptive responses, including those by Nrf2 ([@B181]).

Thus, age-related changes in ROS metabolism can cause damage to mtDNA, but mainly due to an imbalance between mitochondrial biogenesis and mitophagy. Both these processes are closely related to the Nrf2/ARE signal pathway ([@B118]; [@B105]). The mtDNA mutations result from a violation of mtDNA replication and repair ([@B85]), as well as mitophagic dysfunction ([@B52]). In aging organisms, the ability of the Nrf2/ARE cascade to regulate mitochondrial biogenesis is diminished, as it has been demonstrated in rat kidneys ([@B120]) and mouse brain ([@B62]). On the other hand, various tested chemical compounds displayed their pharmacological effects only in old rodents, which might indicate that the system of adaptive responses in young animals does not require additional external stimuli. It was found that the geroprotective effects of EPO ([@B171]), Methylene blue ([@B62]), grape powder ([@B120]), and β-guanidinopropionic acid ([@B61]) can be related to the Nrf2 cascade activation. Several studies demonstrated a decrease in the functional activity of Nrf2 in various organs during aging ([@B148]; [@B141]; [@B41]; [@B160]).

The SKN-1 (Skinhead-1) protein is an Nrf2 ortholog in the *Caenorhabditis elegans* nematode, the most commonly used object for studying longevity. SKN-1 is activated by various external stimuli, including oxidative stress, and induces signaling cascades regulating mitochondrial biogenesis and mitophagy resulting in the renewal of mitochondria and metabolism normalization. In combination with normalization of the mitochondria antioxidant status, coordinated regulation of mitochondrial biogenesis and mitophagy might increase the lifespan of *C. elegans* ([@B116]). The increase of life expectancy because of maintaining of mitochondrial homeostasis connected with the modulation of mitochondrial biogenesis and mitophagy was shown for tomatidine, activating SCN-1 ([@B48])[. D]{.smallcaps}-β-Hydroxybutyrate increased the activity of ETC complexes because of SCN-1 activation, which can also indirectly testify to the activation of mitochondrial biogenesis ([@B45]). However, most of the investigations were focused on gerontoprotection via SKN-1 because of decreasing of oxidative stress and increasing of antioxidant defense. It was demonstrated for hydralazine ([@B36]), resveratrol and its derivatives ([@B51]), pyrroloquinoline ([@B172]), vitamin D3 ([@B97]), catalpol ([@B140]), curcumin ([@B90]), as well as *S*-allylcysteine, *S*-allylmercaptocysteine ([@B112]), and diallyl trisulfide from garlic extract ([@B121]). SKN-1 can also be activated by mild oxidative stress induced by low arsenite doses ([@B138]).

There are no studies showing the relationship between Nrf2 and the insect's mitochondrial biogenesis at the moment. Nevertheless, there are data showing that the inhibition of GSK-3β ([@B25]) and Keap1 loss of function ([@B150]) cause lifespan extension.

The PGC-1α pathway is also involved in the process of age-related violations of mitochondrial biogenesis. Response of PGC-1α to exercise training decreases in old rats ([@B38]). PGC-1α regulators, such as AMPK, SIRT1 and others, are also negatively regulated in the process of aging. The level of SIRT1 decreases in the microglia of old mice ([@B29]). [@B59] showed the strongest age-dependent decrease of SIRT1 level in brain. SIRT1 levels in liver, skeletal muscle and white adipose tissue change less ([@B59]). The activation of AMPK with the help of pharmacological agents and physical exercise was blunted in the skeletal muscle of old rats ([@B130]).

[@B91] reported that PGC-1α structural and functional homologs were not found for several lower organisms, for example for worm, fly and yeasts. Later, dPGC-1/Spargel---a structural homolog of PGC-1α---was found for *Drosophila melanogaster* ([@B56]). The importance of dPGC-1 in *D. melanogaster* mitochondrial biogenesis is shown in numerous studies ([@B157]; [@B129]; [@B104]; [@B180]; [@B167]). dPGC-1-related mitochondrial biogenesis contributes to longevity in Indy (I'm Not Dead Yet) mutant flies ([@B133]). Meldonium increased lifespan and survival rate in fly Huntington disease models via upregulation of the dPGC-1 gene ([@B39]). Silencing of dPGC-1 promotes Parkinsonian phenotypes in flies ([@B101]; [@B110]).

Role of Nrf2 and PGC-1α in Age-Related Neurodegenerative Disease
================================================================

Aging is one of the factors mediating the development of a broad range of neurodegenerative diseases. The structures of the extrapyramidal system, in particular front departments of *substantia nigra pars compacta*, are mainly affected in Parkinson's disease ([@B86]). Mitochondrial biogenesis is inhibited during Parkinson's disease ([@B156]). For this reason, both Nrf2 and PGC-1α are able to be targets for therapy or slowdown of Parkinson's disease pathogenesis. It was shown that moderate physical exercises activate Nrf2-dependent mitochondrial biogenesis, which improves Parkinson's disease symptoms in MPTP ([@B159]) and 6-OHDA models ([@B1]). Dimethyl fumarate and monomethyl fumarate contributed to the treatment of MPTP-induced Parkinson's disease by activating Nrf2-dependent biogenesis ([@B2]). The hereditary form of Parkinson's disease is primarily associated with mutations in the genes encoding PARKIN and PINK1 proteins (PTEN induced kinase 1), which mediate mitophagy ([@B53]). There is a direct connection between Nrf2 and PINK1 as Nrf2 can regulate the expression of *PINK1*, because 4 ARE regions were detected in the promoter of this gene ([@B105]). Nrf2 regulates expression of p62/SQSTM1, which acts as an adapter molecule, which then provides interaction of ubiquitinated molecules directly with the autophagosome ([@B74]). Dimethyl fumarate ([@B87]) and the CCCP (carbonyl cyanide m-chlorophenylhydrazone) ([@B72]) support p62/SQSTM1-dependent mitophagy by activating Nrf2 and contribute to Parkinson's disease therapy. At the moment, Inosin (urate precursor---Nrf2 activator) is on the 3rd stage of clinical trials for the treatment of Parkinson's disease (NCT02642393).

The level of PGC-1α protein decreases during Parkinson diseases in patients ([@B156]) and in SH-SY5Y neuroblastoma cells exposed by MPP^+^ ([@B178]). PGC-1α null mice are much more sensitive to the neurodegenerative effects of MPTP ([@B147]). The protein PARIS (ZNF746) functions as a repressor because of the KRAB domain and repress the activity of PGC-1α ([@B142]). The activity of PARIS in normal functioning neurons is repressed by Parkin ([@B24]), which has ubiquitin Å3-ligase activity ([@B151]). Overexpression of PARIS in the absence of gene Parkin activity causes a decrease of the activity of PGC-1α-dependent mitochondrial biogenesis and a decrease of the mitochondrial number. These effects were not observed after PARIS knockout ([@B146]). Also, compounds such as metformin and glitazone can significantly decrease the risk of Parkinson's disease in diabetes patients via AMPK and PGC-1α ([@B162]; [@B17]).

The main cause of Alzheimer's disease is taupathy (hyperphosphorylation of tau protein with the formation of neurofibrillary tangles) and the accumulation of beta-amyloid plaques (Aβ). These processes are accompanied by extensive oxidative stress and neuroinflammation, so it is logical that Nrf2 is involved in these processes ([@B9]). Nrf2 activators such as Puerarin ([@B183]), Triterpenoid CDDO-methylamide ([@B44]), β-hydroxybutyrate ([@B176]) and others contributed to lowering the level of Aβ and improving rodent cognitive parameters ([@B9]). The effect of Nrf2-dependent reduction of hyperphosphorylated tau was shown for substances such as fisetin ([@B83]), benfotiamine ([@B152]) and dimethyl fumarate ([@B34]). It was shown that it is possible to reduce the level of Aβ and hyperphosphorylated Tau protein simultaneously for methylene blue ([@B149]; [@B177]), sulforaphane ([@B82]) and allicin ([@B184]). Methylene blue is currently undergoing clinical trials for the treatment of Alzheimer's disease (NCT02380573).

The role of PGC-1α during Alzheimer's disease is very ambiguous. On the one hand, the level of *PPARGC1a* expression in postmortem tissues and therapeutic preservation of neuronal *PPARGC1a* expression is able to prevent accumulation of Aβ ([@B125]). On the other hand, *PPARGC1a* overexpression can exacerbate Aβ and hyperphosphorylated tau deposition in mice model of Alzheimer's disease ([@B43]).

Another neurodegenerative disease is Huntington's disease. It is characterized by progressive choreic hyperkinesis and mental disorders caused by striatum atrophy ([@B79]). Nrf2 is a promising target for its treatment. Inhibitors of complex II (3-nitropropionic acid and malonate) can damage its structure and form the symptoms observed during Huntington's disease. Nrf2-deficient mice are more susceptible to inhibitors of complex II, while overexpression of Nrf2, in contrast, protected neurons from the toxicity of malonate ([@B19]). Compounds such as synthetic triterpinoids ([@B144]) and dimethyl fumarate ([@B46]) can improve the symptoms of the disease by Nrf2 activating. PGC-1α is also likely to be involved in the pathogenesis of Huntington's disease. Mutant huntingtin represses *PPARGC1a* gene transcription ([@B35]). Huntington's disease patients are also characterized by a decrease of PGC-1α levels ([@B169]), but it is still not clear if this can be used as therapeutic target for the treatment of Huntington's disease.

Thus, it can be concluded that Nrf2 activation is the most promising direction in the field of neurodegenerative disease therapy. Firstly, it provides antioxidant protection. Reducing the level of oxidative stress can significantly improve the clinical picture of diseases. Secondly, the maintenance of mitochondrial homeostasis, associated with the regulation of the number and functionality of mitochondria, can inhibit degenerative processes in the nervous tissue, significantly slowing the rate of onset of the disease. And although neurodegeneration is considered to be a severe incurable disease, it is believed that slowing down their pathogenesis is a real task, the solution of which will improve the condition of patients, prolong active longevity and delay the terminal phase of the disease as much as possible.
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